Bristol Myers Squibb scores TYK2 OK; ARCH backs mRNA platform play; Illumina’s $8B conundrum; Sizing up Alnylam's win; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Trying to keep up with all the news coming out of ESMO? Well, other than the special event section below, we’ll also be updating the website throughout the weekend. If you prefer a summary, join Arsalan Arif and John Carroll for a virtual recap and analysis on Monday, when we will also publish a special report.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.